NASDAQ:BPMC - Blueprint Medicines Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $103.00
  • Forecasted Upside: 0.70 %
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 9 Buy Ratings
  • 1 Strong Buy Ratings
$102.28
▼ -4.56 (-4.27%)
1 month | 3 months | 12 months
Get New Blueprint Medicines Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BPMC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BPMC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$103.00
▲ +0.70% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Blueprint Medicines in the last 3 months. The average price target is $103.00, with a high forecast of $122.00 and a low forecast of $77.00. The average price target represents a 0.70% upside from the last price of $102.28.
Buy
The current consensus among 14 investment analysts is to buy stock in Blueprint Medicines.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/10/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/8/2019
  • 1 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/6/2019
  • 1 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/4/2020
  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/4/2020
  • 1 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/2/2020
  • 1 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/1/2020
  • 1 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/31/2020

Latest Recommendations

  • 1 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/30/2020WedbushBoost Price Target$102.00 ➝ $115.00Low
i
10/30/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$112.00Low
i
10/29/2020Piper SandlerBoost Price TargetNeutral$77.00 ➝ $81.00Medium
i
10/16/2020Raymond JamesBoost Price TargetPositive ➝ Strong-Buy$106.00 ➝ $122.00Medium
i
10/13/2020Morgan StanleyBoost Price TargetOverweight$92.00 ➝ $100.00Low
i
9/23/2020SVB LeerinkBoost Price TargetOutperform$107.00 ➝ $121.00Medium
i
9/23/2020BMO Capital MarketsBoost Price TargetOutperform$105.00 ➝ $113.00Medium
i
9/23/2020BarclaysBoost Price TargetEqual Weight$77.00 ➝ $90.00Medium
i
Rating by Peter Lawson at Barclays PLC
9/22/2020Raymond JamesReiterated RatingBuyMedium
i
9/2/2020Raymond JamesReiterated RatingBuyHigh
i
7/31/2020HC WainwrightReiterated RatingBuyLow
i
7/27/2020SVB LeerinkBoost Price TargetOutperform$106.00 ➝ $107.00Medium
i
7/15/2020Morgan StanleyBoost Price TargetOverweight$88.00 ➝ $92.00Low
i
7/15/2020BarclaysReiterated RatingHold ➝ NeutralHigh
i
Rating by Peter Lawson at Barclays PLC
7/15/2020Deutsche Bank AktiengesellschaftBoost Price TargetBuy$85.00 ➝ $95.00Medium
i
Rating by Konstantinos Aprilakis at Deutsche Bank Aktiengesellschaft
7/15/2020SVB LeerinkBoost Price TargetOutperform$105.00 ➝ $106.00High
i
7/15/2020HC WainwrightBoost Price TargetBuy$66.00 ➝ $110.00High
i
7/14/2020Robert W. BairdBoost Price TargetOutperform$90.00 ➝ $100.00High
i
7/14/2020Raymond JamesBoost Price TargetPositive ➝ Strong-Buy$95.00 ➝ $106.00High
i
6/8/2020Deutsche Bank AktiengesellschaftBoost Price TargetPositive ➝ Buy$70.00 ➝ $85.00High
i
Rating by Konstantinos Aprilakis at Deutsche Bank Aktiengesellschaft
6/8/2020BMO Capital MarketsBoost Price TargetOutperform$75.00 ➝ $111.00High
i
Rating by George Farmer at BMO Capital Markets
5/7/2020HC WainwrightReiterated RatingBuy$66.00Medium
i
5/4/2020BarclaysInitiated CoverageEqual Weight$59.00Low
i
Rating by Peter Lawson at Barclays PLC
4/30/2020Canaccord GenuityLower Price TargetBuy$115.00 ➝ $100.00Low
i
4/30/2020Morgan StanleyLower Price TargetOverweight$103.00 ➝ $88.00Low
i
4/29/2020JMP SecuritiesLower Price TargetMarket Outperform$107.00 ➝ $103.00Medium
i
4/29/2020BMO Capital MarketsLower Price TargetOutperform$89.00 ➝ $75.00Medium
i
Rating by George Farmer at BMO Capital Markets
4/29/2020SVB LeerinkLower Price TargetOutperform$125.00 ➝ $105.00Medium
i
4/29/2020HC WainwrightLower Price TargetBuy$100.00 ➝ $66.00Medium
i
3/24/2020WedbushReiterated RatingOutperformHigh
i
3/17/2020SVB LeerinkBoost Price TargetOutperform ➝ Positive$116.00 ➝ $125.00Medium
i
3/17/2020BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$74.00 ➝ $89.00High
i
Rating by George Farmer at BMO Capital Markets
3/16/2020CowenInitiated CoverageBuyHigh
i
Rating by Marc Frahm at Cowen Inc
3/16/2020Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$70.00High
i
2/18/2020Morgan StanleyLower Price TargetOverweight$108.00 ➝ $103.00Low
i
Rating by David Lebovitz at Morgan Stanley
2/13/2020CowenReiterated RatingBuyHigh
i
Rating by Marc Frahm at Cowen Inc
1/27/2020BMO Capital MarketsInitiated CoverageMarket Perform$74.00Low
i
1/15/2020WedbushReiterated RatingPositive ➝ Outperform$141.00 ➝ $122.00Low
i
1/10/2020SVB LeerinkBoost Price Target$103.00 ➝ $120.00Low
i
1/9/2020HC WainwrightReiterated RatingBuyMedium
i
Rating by A. Fein at HC Wainwright
12/20/2019Piper Jaffray CompaniesLower Price TargetNeutral$85.00 ➝ $77.00Low
i
Rating by Christopher Raymond at Piper Jaffray Companies
12/10/2019Deutsche Bank AktiengesellschaftLower Price TargetHold$75.00 ➝ $70.00Low
i
12/2/2019Deutsche Bank AktiengesellschaftInitiated CoverageSellMedium
i
11/7/2019HC WainwrightReiterated RatingBuy$100.00Low
i
Rating by A. Fein at HC Wainwright
11/6/2019Raymond JamesUpgradeOutperform ➝ Strong-Buy$106.00 ➝ $112.00Medium
i
10/28/2019Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$110.00 ➝ $75.00High
i
10/22/2019JMP SecuritiesInitiated CoverageOutperform$106.00High
i
10/11/2019Morgan StanleyLower Price TargetOverweight$110.00 ➝ $109.00Low
i
10/3/2019HC WainwrightInitiated CoverageBuy$100.00High
i
Rating by A. Fein at HC Wainwright
9/30/2019CowenReiterated RatingBuyHigh
i
Rating by Marc Frahm at Cowen Inc
9/12/2019Raymond JamesUpgradeMarket Perform ➝ OutperformLow
i
9/9/2019Piper Jaffray CompaniesReiterated RatingHoldLow
i
Rating by Christopher Raymond at Piper Jaffray Companies
9/9/2019CowenReiterated RatingBuyHigh
i
Rating by Marc Frahm at Cowen Inc
8/29/2019Piper Jaffray CompaniesInitiated CoverageNeutral$85.00Low
i
8/14/2019Raymond JamesReiterated RatingMkt Perform ➝ Market PerformHigh
i
8/2/2019Canaccord GenuityBoost Price TargetBuy$105.00 ➝ $120.00High
i
7/18/2019Robert W. BairdInitiated CoverageOutperform$120.00Medium
i
7/18/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$110.00Medium
i
6/17/2019CowenReiterated RatingBuyLow
i
Rating by Marc Frahm at Cowen Inc
6/2/2019CowenReiterated RatingBuyHigh
i
Rating by Marc Frahm at Cowen Inc
5/23/2019The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$125.00High
i
4/3/2019Morgan StanleyInitiated CoverageOverweight$112.00Low
i
3/28/2019CowenReiterated RatingBuyHigh
i
Rating by Marc Frahm at Cowen Inc
2/26/2019WedbushReiterated RatingOutperformHigh
i
Rating by D. Nierengarten at Wedbush
2/26/2019CowenReiterated RatingBuyMedium
i
Rating by Marc Frahm at Cowen Inc
1/7/2019WedbushReiterated RatingOutperform$103.00High
i
11/15/2018CowenReiterated RatingBuyHigh
i
Rating by Marc Frahm at Cowen Inc
10/22/2018WedbushReiterated RatingOutperform$101.00Medium
i
10/8/2018WedbushReiterated RatingOutperform$101.00Low
i
10/7/2018CowenReiterated RatingBuyLow
i
Rating by Marc Frahm at Cowen Inc
9/25/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$105.00Medium
i
Rating by A. Berens at SVB Leerink LLC
9/18/2018GuggenheimInitiated CoverageBuy$102.00High
i
8/1/2018CowenReiterated RatingBuyHigh
i
Rating by Marc Frahm at Cowen Inc
6/4/2018JMP SecuritiesLower Price TargetMarket Outperform ➝ Buy$109.00 ➝ $103.00High
i
Rating by Konstantinos Aprilakis at JMP Securities
4/16/2018WedbushBoost Price TargetOutperform ➝ Outperform$98.00 ➝ $106.00High
i
4/16/2018JMP SecuritiesSet Price TargetBuy$97.00 ➝ $109.00High
i
Rating by Konstantinos Aprilakis at JMP Securities
2/21/2018CowenReiterated RatingBuyLow
i
12/11/2017The Goldman Sachs GroupBoost Price TargetBuy ➝ Buy$82.00 ➝ $99.00High
i
12/11/2017JMP SecuritiesBoost Price TargetOutperform$88.00 ➝ $97.00High
i
12/10/2017Raymond JamesSet Price TargetBuy$82.00High
i
Rating by Laura Chico at Raymond James
11/10/2017CowenReiterated RatingBuyN/A
i
11/6/2017WedbushReiterated RatingOutperform$70.00 ➝ $82.00N/A
i
11/1/2017Canaccord GenuityReiterated RatingBuy$66.00 ➝ $80.00N/A
i
Rating by Arlinda Lee at Canaccord Genuity
10/31/2017CowenReiterated RatingBuyN/A
i
10/23/2017Morgan StanleyBoost Price TargetOverweight$45.00 ➝ $78.00N/A
i
9/29/2017DA DavidsonInitiated CoverageBuy$90.00High
i
9/29/2017BTIG ResearchInitiated CoverageBuy ➝ Buy$90.00High
i
9/20/2017The Goldman Sachs GroupReiterated RatingBuy$64.00 ➝ $79.00Low
i
9/20/2017Canaccord GenuityBoost Price TargetBuy$56.00 ➝ $66.00Medium
i
Rating by Arlinda Lee at Canaccord Genuity
9/11/2017Canaccord GenuityReiterated RatingBuy$56.00Low
i
Rating by Arlinda Lee at Canaccord Genuity
9/5/2017Jefferies Financial GroupReiterated RatingBuy$56.00Medium
i
8/22/2017WedbushReiterated RatingOutperform$66.00High
i
8/2/2017Canaccord GenuitySet Price TargetBuy$52.00 ➝ $56.00Medium
i
Rating by Arlinda Lee at Canaccord Genuity
6/6/2017Canaccord GenuitySet Price TargetBuy$52.00Low
i
Rating by Arlinda Lee at Canaccord Genuity
6/6/2017CowenReiterated RatingBuyLow
i
6/6/2017WedbushReiterated RatingOutperform$55.00Low
i
5/4/2017Jefferies Financial GroupBoost Price TargetBuy$42.00 ➝ $52.00Medium
i
Rating by Eun Yang at Jefferies Financial Group Inc.
4/5/2017WedbushBoost Price TargetOutperform ➝ Outperform$43.00 ➝ $50.00Low
i
4/4/2017Canaccord GenuityBoost Price TargetBuy$40.00 ➝ $42.00Low
i
Rating by Arlinda Lee at Canaccord Genuity
3/22/2017JMP SecuritiesInitiated CoverageOutperform$37.00 ➝ $46.00Low
i
Rating by Michael King at JMP Securities
3/13/2017The Goldman Sachs GroupUpgradeNeutral ➝ Buy$52.00High
i
2/15/2017Morgan StanleyInitiated CoverageOverweight$45.00N/A
i
12/14/2016Jefferies Financial GroupInitiated CoverageBuy$40.00N/A
i
12/6/2016WedbushReiterated RatingOutperform$43.00N/A
i
12/5/2016CowenReiterated RatingBuy$38.33 ➝ $33.19N/A
i
12/1/2016JMP SecuritiesReiterated RatingBuyN/A
i
Rating by Michael King at JMP Securities
11/29/2016WedbushReiterated RatingOutperform$43.00 ➝ $41.00N/A
i
11/12/2016Canaccord GenuitySet Price TargetBuy$35.00N/A
i
Rating by Arlinda Lee at Canaccord Genuity
11/10/2016WedbushReiterated RatingOutperform$41.00N/A
i
11/3/2016CowenReiterated RatingBuyN/A
i
Rating by Eric Schmidt at Cowen Inc
8/9/2016CowenReiterated RatingBuyN/A
i
Rating by Eric Schmidt at Cowen Inc
8/9/2016WedbushReiterated RatingOutperform$41.00N/A
i
8/5/2016Canaccord GenuityInitiated Coverage` ➝ Buy$26.00N/A
i
5/27/2016Raymond JamesInitiated CoverageOutperform$23.00N/A
i
5/10/2016CowenReiterated RatingBuyN/A
i
Rating by Eric Schmidt at Cowen Inc
3/15/2016WedbushReiterated RatingOutperform$41.00N/A
i
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$54.00 ➝ $37.00N/A
i
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$54.00 ➝ $37.00N/A
i
2/22/2016The Goldman Sachs GroupLower Price Target$26.00 ➝ $15.00N/A
i
(Data available from 10/31/2015 forward)
Blueprint Medicines logo
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies. In addition, the company is developing BLU-782, an inhibitor targeting the kinase ALK2 for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the ALK2 gene, ACVR1. The company has collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $102.28
$100.98
$106.08

50 Day Range

MA: $91.94
$66.45
$106.84

52 Week Range

Now: $102.28
$43.29
$108.50

Volume

625,251 shs

Average Volume

393,675 shs

Market Capitalization

$5.65 billion

P/E Ratio

18.87

Dividend Yield

N/A

Beta

0.87